Compare SCL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCL | HROW |
|---|---|---|
| Founded | 1932 | 1998 |
| Country | United States | United States |
| Employees | N/A | 373 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1994 | N/A |
| Metric | SCL | HROW |
|---|---|---|
| Price | $56.85 | $44.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $75.00 | $69.86 |
| AVG Volume (30 Days) | 149.3K | ★ 849.0K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,803,737,000.00 | N/A |
| Revenue This Year | $6.60 | $31.62 |
| Revenue Next Year | $5.27 | $50.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $41.82 | $28.54 |
| 52 Week High | $68.00 | $54.98 |
| Indicator | SCL | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 66.96 | 67.84 |
| Support Level | $49.36 | $44.30 |
| Resistance Level | $68.00 | $51.01 |
| Average True Range (ATR) | 1.63 | 2.12 |
| MACD | 0.24 | 0.25 |
| Stochastic Oscillator | 97.01 | 89.11 |
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.